A Phase I Safety and Tolerability Study of LBH589 in Combination With Sorafenib in Patients With Advanced Renal Cell Carcinoma, Soft Tissue Sarcoma, and Non-small Cell Lung Carcinoma (NSCLC) of Non-squamous Histologies.
Phase of Trial: Phase I
Latest Information Update: 06 Mar 2017
At a glance
- Drugs Panobinostat (Primary) ; Sorafenib
- Indications Non-small cell lung cancer; Renal cancer
- Focus Adverse reactions
- 28 Feb 2017 Status changed from active, no longer recruiting to completed.
- 07 Apr 2015 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
- 07 Nov 2009 New trial record